Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12980850 | 0.81 | ALDH1A1 (0.46) | AOC3ALDH1A1GAALMNADRD3 | |
| SCHEMBL8921081 | 0.81 | ALDH1A1 (0.46) | AOC3ALDH1A1GAALMNADRD3 | |
| SCHEMBL10140990 | 0.80 | ALDH1A1 (0.43) | AOC3ALDH1A1GAASLC6A4 | |
| SCHEMBL6092822 | 0.79 | BRD4 (0.55) | AOC3BRD4ALDH1A1GAALMNA | |
| SCHEMBL755751 | 0.79 | ALDH1A1 (0.47) | AOC3BRD4ALDH1A1GAALMNA | |
| SCHEMBL10140569 | 0.79 | POLB (0.38) | ALDH1A1LMNASMN1; SMN2SLC6A4SLC6A3 | |
| SCHEMBL8917155 | 0.79 | SMN1; SMN2 (0.38) | ALDH1A1GAALMNASMN1; SMN2HTT | |
| SCHEMBL13154965 | 0.78 | ALDH1A1 (0.40) | AOC3BRD4ALDH1A1GAALMNA | |
| Hydrochloric Acid SCHEMBL7259111 | 0.78 | BRD4 (0.53) | AOC3BRD4ALDH1A1GAALMNA | |
| SCHEMBL13748371 | 0.78 | MDM2 (0.48) | AOC3BRD4ALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | AOC3 1562/4885BRD4 1541/4885ALDH1A1 229/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | AOC3 2292/4885BRD4 319/4885ALDH1A1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.